Gov't advisers revisit heart risks posed by painkillers - WMBB News 13 - The Panhandle's News Leader

Gov't advisers revisit heart risks posed by painkillers

Updated:
© iStockphoto.com / Selahattin Bayram © iStockphoto.com / Selahattin Bayram
  • What's Going AroundMore>>

  • What's Going Around - August 20th

    What's Going Around - August 20th

    Wednesday, August 20 2014 1:08 PM EDT2014-08-20 17:08:58 GMT
    We all dread getting that sore feeling in our throat. It can be one of the first signs we're getting sick.More >>
    We all dread getting that sore feeling in our throat. It can be one of the first signs we're getting sick.More >>
  • What's Going Around - August 12th

    What's Going Around - August 12th

    Wednesday, August 13 2014 12:02 AM EDT2014-08-13 04:02:37 GMT
    There's a stomach illness going around, and there are some symptoms you need to be aware of to keep your family healthy.More >>
    There's a stomach illness going around, and there are some symptoms you need to be aware of to keep your family healthy.More >>

MONDAY, Feb. 10, 2014 (HealthDay News) -- Naproxen -- the key pain reliever in Aleve -- seems safer for the heart than other popular anti-inflammatory drugs such as ibuprofen (Advil and Motrin), U.S. health officials say.

And it's possible that labeling will soon reflect that finding.

Advisers to the U.S. Food and Drug Administration are meeting Monday and Tuesday to discuss cardiac risks associated with non-steroidal anti-inflammatory drugs, sometimes called NSAIDs.

Millions of people take these medicines, which also include the prescription drug Celebrex, to relieve muscle aches, headaches and pain from arthritis and injuries.

Since 2005, labeling laws have required a heart warning on these anti-inflammatory drugs. That stemmed from Merck's withdrawal of the NSAID Vioxx from the market in 2004 because of a notable increased risk of heart attack among Vioxx users.

But naproxen doesn't seem to carry the same risks as the other NSAIDs, an FDA panel recently concluded after a safety review involving 350,000 people using different pain relievers. The panel posted its findings online last week.

If the FDA does approve a labeling change, that could make Aleve and other naproxen-containing drugs the preferred drug for patients who have a risk of heart problems, Ira Loss, a pharmaceutical analyst with Washington Analysis, told the Associated Press. However, all NSAIDs will still need to warn of risks for internal bleeding and ulceration, Loss said.

The FDA isn't required to follow its advisory panel's recommendations, but it frequently does.

Aspirin, another type of NSAID, isn't a focus of this week's hearings.

More information

The American College of Rheumatology has more about pain relievers.

Copyright © 2014 HealthDay. All rights reserved.

*DISCLAIMER*: The information contained in or provided through this site section is intended for general consumer understanding and education only and is not intended to be and is not a substitute for professional advice. Use of this site section and any information contained on or provided through this site section is at your own risk and any information contained on or provided through this site section is provided on an "as is" basis without any representations or warranties.